Quick verdict
Hims & Hers is the better pick for most patients on overall scoring. Same-day prescription, no lock-in, and brand-name confidence. The famous $199 compounded era ended in March 2026 after the Novo Nordisk settlement; new patients now route to branded products only.
That said, 9amHealth wins on specific dimensions. 9amHealth treats GLP-1 as one tool inside a broader cardiometabolic program. Strong employer and insurance relationships, branded-first medication strategy, labs included. Best fit for patients with comorbidities, not pure weight-loss buyers.
Side-by-side
| Hims & Hers | 9amHealth | |
|---|---|---|
| Starts from | $199/mo (incl. medication) | $25/mo (+ med separate) |
| Lock-in | Month-to-month | Month-to-month |
| Time to prescription | 1 day | 5 days |
| Consultation type | Asynchronous | Synchronous |
| Affiliate network | Impact | Direct |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| Hims & Hers | 9amHealth | |
|---|---|---|
| Pricing transparency | 7/10 | 7/10 |
| Cancellation terms | 9/10 | 8/10 |
| Onboarding experience | 9/10 | 6/10 |
| Medication options | 7/10 | 7/10 |
| Member outcomes | 5/10 | 8/10 |
When to choose Hims & Hers
Patients who want a fast, low-friction async path to a branded GLP-1 prescription with predictable all-in monthly pricing.
When to choose 9amHealth
Patients with diabetes, prediabetes, or cardiovascular risk who want GLP-1 inside comprehensive metabolic care.
FAQ
Is Hims & Hers cheaper than 9amHealth?
Can I switch from Hims & Hers to 9amHealth mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →